The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.
A 3-year study found that most patients with moderate to severe ulcerative colitis who responded to initial upadacitinib treatment stayed in remission through 96 weeks, with manageable side effects and consistent results across dosage groups.
Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.
A large French clinical trial found that patients with moderate to severe ARDS who received sevoflurane had fewer ventilator-free days and lower 90-day survival than those sedated with propofol.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
BAL detected pathogens in 61% of cases and led to treatment changes in nearly 9 out of 10 immunocompromised children with acute respiratory illness, according to a new 5-year study.